PRME · XBRL financial data

Prime Medicine financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PRME's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	0	0	2,983	4,632
Research and development	86,725	147,905	155,289	160,636
General and administrative	29,819	43,387	50,161	52,346
Total operating expenses	116,544	204,792	205,450	212,982
Operating income (loss)	(116,544)	(204,792)	(202,467)	(208,350)
Interest income	—	2,811	3,522	4,149
Other income (expense)	1,903	8,762	41	148
Income tax expense (benefit)	(948)	(279)	0	0
Net income (loss)	(121,821)	(198,133)	(195,882)	(201,142)
Earnings per share, basic USD per share	(4.19)	(2.18)	(1.65)	(1.35)
Earnings per share, diluted USD per share	(4.19)	(2.18)	(1.65)	(1.35)
Weighted average shares, basic thousands of shares	33,891	90,969	118,600	148,759
Weighted average shares, diluted thousands of shares	33,891	90,969	118,600	148,759

Fiscal years (PRME's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	187,620	41,574	182,476	63,032
Marketable securities	98,467	—	—	114,648
Prepaid and other current assets	2,697	—	—	—
Total current assets	296,618	142,976	211,886	181,293
Property and equipment, net	19,009	22,659	24,404	20,572
Right-of-use asset	29,545	13,941	47,156	126,177
Total assets	360,314	193,851	297,508	342,733
Accounts payable	4,332	19,537	11,351	8,887
Accrued liabilities	10,688	14,110	15,904	12,600
Total current liabilities	26,714	56,423	37,961	37,448
Lease liability, non-current	17,051	4,357	37,180	108,290
Total liabilities	44,044	60,780	144,359	221,865
Accumulated deficit	(293,197)	(491,330)	(687,212)	(888,354)
Total stockholders' equity	316,270	133,071	153,149	120,868
Total liabilities and equity	360,314	193,851	297,508	342,733
Common shares outstanding (cover page) thousands of shares	97,246	119,939	131,161	180,552

Fiscal years (PRME's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(121,821)	(198,133)	(195,882)	(201,142)
Stock-based compensation	6,459	13,910	26,068	29,268
Depreciation and amortization	2,224	4,653	6,128	7,321
Net cash from operating activities	(131,827)	(165,412)	(122,865)	(162,564)
Purchases of property and equipment	16,095	8,724	7,294	4,531
Net cash from investing activities	(47,096)	18,711	68,457	(108,763)
Proceeds from issuing common stock	—	0	38,081	0
Net cash from financing activities	181,494	655	195,876	151,512
Net change in cash	2,571	(146,046)	141,468	(119,815)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Prime Medicine	47,451	not reported	(41,046)*	181.4M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Heron Therapeutics	20,721	not reported	(2,213)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Annexon	199,270	not reported	(48,007)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Aldeyra Therapeutics	40,975	not reported	(4,124)*	60.4M	—	Q3 FY26 10-QSep 30, 2026
Sagimet Biosciences	165,896	not reported	(11,099)*	not reported	23.2 quarters	Q2 FY26 10-QJun 30, 2026
DBV Technologies	165,700	1,600	(51,500)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Corvus Pharmaceuticals	15,013	not reported	(12,215)*	84.4M	15.7 quarters	Q3 FY26 10-QSep 30, 2026
Verastem	172,801	24,012	(33,593)*	126.0M	4.0 quarters	Q3 FY26 10-QSep 30, 2026
Lifecore Biomedical	23,035	25,322	6,946*	37.9M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 11:44 PM ET. The filing on SEC.gov is the record.